Aura Biosciences, Inc. (AURA) Stock Price & Analysis

Aura Biosciences, Inc. (AURA) closed at USD 6.4 on Wednesday, October 28, 2026, up 1.59% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 6.3; the Oct 28, 2026 session ranged USD 6.21–6.41 on volume of 541,814 shares. Market capitalization is $663.71M, with a 52-week range of USD 4.73–9.54 (NGM). Source: Nexqual, retrieved October 28, 2026 at 23:06 UTC.

Also available as compact Markdown for AI agents: nexqual.com/AURA.md

Key facts (AURA)

• Insider open-market sales, last ~7 months: 3 Form 4 filings, $39.2M; 3 not under a Rule 10b5-1 plan ($39.2M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.83 on a 1–5 scale) (6 analysts), mean target USD 16.6 (range 12–23).
• Total return with dividends: 1Y +4.2% vs S&P 500 +13.6%; 5Y -56.8% vs S&P 500 +79.8%.
• Next earnings: 2026-11-12, EPS estimate USD -0.37, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AURA)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (AURA)

P/B 2.1x · FCF yield -15.57% · Earnings yield -19.74%

Insider sales (SEC Form 4, open-market, last ~7 months) (AURA)

0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (AURA)

Consensus Buy (mean 1.83 on a 1–5 scale), 6 analysts; mean target USD 16.6 (low 12, high 23).

Rating changes, last 120 days:

Total return (dividends reinvested) (AURA)

AURA earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

AURA recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

AURA suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 30, 2026.

AURA company outlook (results filed Aug 11, 2026)

• “Topline data from the 15-month primary endpoint remain on track for the second half of 2027, consistent with previously communicated guidance.”
• “Aura expects to provide an update on both programs, including guidance on study completion, in Q1 2027.”
• “Together with disciplined capital allocation, these actions are expected to extend the Company's projected cash runway into the first half of 2029 to support execution of the Phase 3 CoMpass trial, advancement of its additional ocular oncology programs and preparation for potential commercialization.”
• “The restructuring plan is expected to be substantially complete by the end of the third quarter of 2026.”

Quoted word-for-word from the SEC 8-K results press release.

AURA analyst estimates and revisions

Key Statistics (as of October 28, 2026 at 23:06 UTC)

Technical Analysis (AURA)

Nexqual's technical model rates AURA "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 28, 2026 at 23:06 UTC.

Analyst Ratings (AURA)

Wall Street analysts rate AURA "Buy" based on 6 analysts, with a mean price target of USD 16.6 (range USD 12–23), per Nexqual as of October 28, 2026 at 23:06 UTC.

Earnings (AURA)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 23:06 UTC.

Financials & Fundamentals (AURA)

Source: Nexqual, October 28, 2026 at 23:06 UTC.

Financial Health Score (AURA)

Nexqual rates Aura Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of October 28, 2026 at 23:06 UTC.

Ownership (AURA)

Source: Nexqual, October 28, 2026 at 23:06 UTC.

Leadership (AURA)

Aura Biosciences, Inc. is led by Natalie C. Holles, President, CEO & Director, per Nexqual as of October 28, 2026 at 23:06 UTC.

Major Backers & Investors (AURA)

Notable institutional backers of Aura Biosciences, Inc. include TCG Crossover Management, LLC, Montanova Capital LLC, Frazier Life Sciences Management, L.P. , according to Nexqual as of October 28, 2026 at 23:06 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 23:06 UTC.

From Aura Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• Mark Plavsic, Ph.D. is our Chief Technology Officer and brings 30 years of global biopharmaceutical experience including end-to-end technical operations in the United States, Europe, and Australasia and successful translation and scale-up of complex biologics from preclinical development through commercial launch and distribution.
• Based on the results of the Phase 3 trial, if positive, and a lack of therapies approved for the treatment of this rare disease, with the current SoC with radiotherapy causing patients irreversible vision loss, the FDA and EMA may agree to grant approval based on a single Phase 3 trial.
• We believe the breadth and depth of experience amongst our management team will enable us to advance the clinical and development strategy for bel-sar and, if approved, its commercialization.
• While there are multiple drugs in development, we believe our competitive advantage as an early intervention approach may help reduce the risk of recurrence and metastasis, with a potentially reduced treatment burden for patients.

Partnerships

• Due to our preclinical data and robust publications in collaboration with our scientific founder at the National Institutes of Health, or NIH, demonstrating the binding of our proprietary VLPs to tumor associated GAGs across a wide range of solid tumors, we plan to expand our clinical pipeline across multiple solid cancer indications.
• The 2014 Exclusive Agreement required a one-time upfront license issue fee of $0.1 million and requires aggregate milestone payments of up to $0.2 million upon certain regulatory and development milestones.

Legal & Regulatory Risks (Item 1A, quoted)

• Our novel VDC product candidates are based on a technology that we are in the process of developing. We expect the novel nature of such product candidates to create further challenges in obtaining regulatory approval. As a result, our ability to develop product candidates and obtain regulatory approval may be significantly impacted.
• We are conducting a clinical trial outside the United States, and we may in the future conduct additional clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
• The FDA may reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.
• The FDA's agreement to a Special Protocol Assessment, or SPA, with respect to the study design of our global Phase 3 trial of bel-sar for the treatment of early choroidal melanoma does not guarantee any particular outcome from regulatory review, including ultimate approval, and may not lead to a successful review or approval process.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 23:06 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt